The Value of Plasmatic HoxD10 Methylation for Detection of Gastric Cancer and Precancerous Lesions

• 作 者: Mengzhao Luo Bixia Huang Zhenghua Lin Xueqing Chen Liangjing Wang Shujie Chen
• 机 构: Institute of Gastroenterology, Zhejiang University, Hangzhou 310016, Zhejiang Province, China;Depart
• 出 处: 2017中国医师协会消化医师分会年会
• 发表日期: 2017年10期

　　Homeobox D10 (HoxD10) is a candidate tumor suppressor that was silenced by promoter meyhylation in gastric cancer (GC).We studied HoxD10 promoter methylation in plasma as noninvasive biomarker to detect and monitor GC.MSP assays were used to measure HoxD10 promoter methylation in plasma of 38 healthy volunteers,55 patients with gastric intraepithelial neoplasia (GIN),123 GC patients and 17 post-treatment (PT) patients.We discovered that the ratio of HoxD10 methylation was 0% in healthy controls,34.55% in GIN,46.34% in GC and 17.65% in the PT group.The methylation level was significantly higher in GIN or GC than in the normal control group (p<0.01) and the methylation rate of the post-treatment group was significantly lower than that in the GC group (p <0.05).In GC patients,HoxD10 promoter methylation was correlated to tumor invasion depth (p<0.05),while no association was found in sex,age,tumor size,TNM stage,CEA and H.pylori infection (p>0.05).Associated with HoxD10 methylation and CEA,the sensitivity was conspicuously higher than CEA or HoxD10 methylation alone.Conclusively,HoxD10 promoter methylation in plasma exhibited an exceedingly high ability for GC diagnosis and monitoring the development and prognosis of GC.